News

cardiologists heart doctors

The J-Valve System is associated with positive 10-year outcomes for patients with severe AR, according to new research out of China. It also performs well in patients with severe AS.

heart drugs with stethoscope

An experimental oral PCSK9 inhibitor is associated with LDL-C reductions that could prove to be a game-changer for patient care. 

SCAI has shared a new call to action as an observance of American Heart Month. The group is asking Congress to pass new pieces of legislation that could improve care for PAD patients and get important medical devices in the hands of interventional cardiologists.

Cerepak Detachable Coil Systems

Several detachable coil systems are being recalled due to a higher-than-expected failure to detach rate. Customers should not use them going forward.

the words "FDA recall" on a board

New Jersey-based Zydus Pharmaceuticals has recalled nearly 23,000 bottles of its icosapent ethyl capsules due to leakage issues that may have weakened their effectiveness. 

heart surgery surgeons

Survival rates are high for both men and women presenting with BAV disease, according to a new analysis of nearly 28,000 SAVR patients.

Open surgical bypass is the gold standard, but endovascular therapies may provide value for high-risk patients with long femoropopliteal lesions.

The cardiologist at the head of an influential CDC panel sees serious problems with modern vaccine policies. While many experts seem to disagree, one organization has jumped to his defense. 

Balloon valvuloplasty months after implantation is a safe and effective treatment option for patients with transcatheter heart valve (THV) dysfunction, according to a new analysis published in the Journal of the American College of Cardiology

The median time from heart valve implantation to balloon dilatation was 4.6 months.

Thumbnail

“Improving ancillary shielding barriers is paramount,” according to the authors of a brand new analysis. 

Hello Heart, a digital therapeutics company that focuses on heart health, has raised $70 million in a Series D funding round.

TAVR Medtronic Evolut EXPAND TAVR II Pivotal Trial,

The trial is expected to enroll up to 650 patients from as many as 100 different facilities throughout the world.

Around the web

Tim Szczykutowicz, PhD, associate professor radiology, University of Wisconsin Madison, explains the new technology developments in GE HealthCare's  FDA 510(k)-pending photon-counting CT scanner.